Drug General Information
Drug ID
D00KHD
Former ID
DIB008847
Drug Name
TAK-128
Synonyms
Y-128
Indication Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] Phase 2 [521733]
Company
Mitsubishi Pharma Corp
Target and Pathway
Target(s) Thromboxane A2 receptor Target Info Modulator [521733]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Platelet activation
Reactome Prostanoid ligand receptors
G alpha (q) signalling events
G alpha (12/13) signalling events
Thromboxane signalling through TP receptor
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
Signal amplification
GPCR ligand binding
GPCR downstream signaling
References
Ref 521733ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
Ref 521733ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.